{"product_id":"oakstone-update-in-urologic-oncology-2026","title":"Oakstone Update in Urologic Oncology 2026","description":"\u003ch1 class=\"product_title entry-title\"\u003eOakstone Update in Urologic Oncology 2026\u003c\/h1\u003e\r\n\u003cstrong\u003e+ Target Audience: urologists, urologic oncologists, medical oncologists\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eUpdates for GU Cancer Care\u003c\/strong\u003e\r\n\r\nStrengthen your clinical approach with the \u003cem\u003eUpdate in Urologic Oncology\u003c\/em\u003e. This high-yield continuing medical education course is an all-encompassing look at the full spectrum of genitourinary oncology. From new guidelines and recent trials to updated diagnostics and the latest therapeutic approaches, you’ll gain practical tools for board prep and knowledge you can use in your daily practice to improve care coordination, and optimize patient outcomes.\r\n\r\nIn this online video program, you’ll explore:\r\n\u003cul\u003e\r\n \t\u003cli\u003eComprehensive coverage of disease-specific diagnosis, treatment algorithms, and survivorship considerations.\u003c\/li\u003e\r\n \t\u003cli\u003eActionable updates on systemic therapies, immuno-oncology, biomarkers, and advanced imaging.\u003c\/li\u003e\r\n \t\u003cli\u003eExpert insights into multidisciplinary care coordination, value-based care delivery, and patient-centered decision-making.\u003c\/li\u003e\r\n \t\u003cli\u003ePractical tools to translate new evidence into clinical workflows and improve outcomes across diverse practice settings.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eDate of Original Release:\u003c\/strong\u003e May 31, 2026\r\n\u003cstrong\u003eEstimated Time to Complete:\u003c\/strong\u003e 22.75 hours\r\n\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\r\n\u003cem\u003eUpon completion of this activity, you should be able to:\u003c\/em\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterpret the latest NCCN\/AUA guideline updates and pivotal trial data to optimize management of localized and advanced genitourinary malignancies.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate imaging, genomic, molecular, and biomarker information into personalized diagnostic and treatment algorithms.\u003c\/li\u003e\r\n \t\u003cli\u003eFormulate multidisciplinary treatment plans that appropriately sequence surgery, systemic therapy, radiation, and survivorship strategies.\u003c\/li\u003e\r\n \t\u003cli\u003eApply evidence-based multidisciplinary and survivorship strategies to improve quality and coordination of care in genitourinary oncology\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate emerging therapies, clinical-trial data, and evolving standards of care relevant to genitourinary oncology practice.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eIntended Audience\u003c\/h3\u003e\r\nThis activity was designed for urologists, urologic oncologists, and medical oncologists.\r\n\r\n \r\n\r\n\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\r\n\r\nUnderstanding the Global Epidemiology and Burden of Genitourinary Cancers – \u003cem\u003eAaron Laviana, MD, MBA\u003c\/em\u003e\r\n\r\nClinical Trial Design and Interpretation for the Busy Surgeon – \u003cem\u003eKristian Stensland, MD, MPH, MS\u003c\/em\u003e\r\n\r\nContemporary PSA-Based Screening for Prostate Cancer – Evidence, Controversies, and Risk-Adapted Approach – \u003cem\u003eUdit Singhal, MD\u003c\/em\u003e\r\n\r\nProstate Biopsy – Techniques, Pitfalls, and Future Directions – \u003cem\u003eKara Watts, MD\u003c\/em\u003e\r\n\r\nGenomic Classifiers Part 1 – Prostate Cancer Screening Risk Assessment – \u003cem\u003eRandy A. Vince, Jr., MD, MS\u003c\/em\u003e\r\n\r\nGenomic Classifiers Part 2 – Prostate Cancer Risk Stratification – \u003cem\u003eRandy A. Vince, Jr., MD, MS\u003c\/em\u003e\r\n\r\nActive Surveillance in Prostate Cancer – \u003cem\u003eKristen R. Scarpato, MD, MPH\u003c\/em\u003e\r\n\r\nRobotic-Assisted Radical Prostatectomy – Novel Techniques – \u003cem\u003eKeith J. Kowalczyk, MD\u003c\/em\u003e\r\n\r\nRadiation Therapy for Prostate Cancer – Low and Intermediate Risk Categories – \u003cem\u003eKhush Singh Aujla, MD, MHA\u003c\/em\u003e\r\n\r\nRadiation Therapy for Prostate Cancer – High-Risk Localized and Locally Advanced Categories – \u003cem\u003eKhush Singh Aujla, MD, MHA\u003c\/em\u003e\r\n\r\nFocal Therapy for Prostate Cancer – \u003cem\u003eKara Watts, MD\u003c\/em\u003e\r\n\r\nPrinciples of Prostate Cancer Survivorship after Radical Prostatectomy – Erectile Dysfunction and Urinary Incontinence – \u003cem\u003eNiels V. Johnsen, MD, MPH, FACS\u003c\/em\u003e\r\n\r\nligometastatic and Biochemical Recurrence of Prostate Cancer – \u003cem\u003eMohummad Minhaj Siddiqui, MD FACS\u003c\/em\u003e\r\n\r\nManagement of Advanced Prostate Cancer for the Urologist – Part 1 – De novo Locally Advanced Systemic Therapy – \u003cem\u003eCatherine Fahey, MD, PhD\u003c\/em\u003e\r\n\r\nManagement of Advanced Prostate Cancer for the Urologist – Part 2 – De novo Metastatic Systemic Therapy – \u003cem\u003eCatherine Fahey, MD, PhD\u003c\/em\u003e\r\n\r\nManaging Treatment-Related Adverse Effects, Sexual Health, and Survivorship after Prostate Cancer Treatment – \u003cem\u003eCameron J. Britton, MD\u003c\/em\u003e\r\n\r\nContemporary Workup of Microscopic and Gross Hematuria – \u003cem\u003eMary Beth Westerman, MD\u003c\/em\u003e\r\n\r\nNon-Muscle-Invasive Bladder Cancer Part 1 – Diagnosis and Risk Stratification – \u003cem\u003eHelen Y. Hougen, MD\u003c\/em\u003e\r\n\r\nNon-Muscle-Invasive Bladder Cancer Part 2 – Treatments – \u003cem\u003eHelen Y. Hougen, MD\u003c\/em\u003e\r\n\r\nNeo-Adjuvant Chemotherapy Prior to Radical Cystectomy for Muscle Invasive Bladder Cancer – \u003cem\u003eParminder Singh, MD\u003c\/em\u003e\r\n\r\nAdjuvant Therapy for Muscle – Invasive Bladder Cancer – \u003cem\u003eParminder Singh, MD\u003c\/em\u003e\r\n\r\nRadical Cystectomy for Muscle-Invasive Bladder Cancer – Surgical Approaches and Urinary Diversions – \u003cem\u003eLaura Bukavina, MD, MPH, MSc\u003c\/em\u003e\r\n\r\nTrimodality Bladder-Preservation Protocols for MIBC – \u003cem\u003eWesley Yip, MD\u003c\/em\u003e\r\n\r\nUpper-Tract Urothelial Carcinoma – Diagnosis and Treatment – \u003cem\u003eAmy Luckenbaugh, MD, FACS\u003c\/em\u003e\r\n\r\nNovel Imaging Strategies in Renal Mass Staging and Detection – \u003cem\u003eAva Saidian, MD\u003c\/em\u003e\r\n\r\nManagement of Small Renal Masses – \u003cem\u003eDaniel D. Shapiro, MD, FACS\u003c\/em\u003e\r\n\r\nSurgical Approaches for Renal Masses – Overview of Open Surgery, and Anatomical Considerations – \u003cem\u003eKelvin A. Moses, MD, PhD, FACS\u003c\/em\u003e\r\n\r\nSmall Renal Masses – Overview of Robotic Approaches – \u003cem\u003eDaniel D. Joyce, MD, MS\u003c\/em\u003e\r\n\r\nAdvanced RCC – Venous Tumor Thrombi and Cytoreductive Nephrectomy – \u003cem\u003eVidit Sharma, MD, MS\u003c\/em\u003e\r\n\r\nRenal Cell Carcinoma – Implications for Radiation Therapy – \u003cem\u003eDakim Gaines, MD, PhD\u003c\/em\u003e\r\n\r\nThe Systemic Therapy Landscape for RCC – \u003cem\u003eKaty Beckermann, MD, PhD\u003c\/em\u003e\r\n\r\nNon-Clear-Cell Renal Masses and Hereditary RCC Syndromes – \u003cem\u003eAllison May, MD\u003c\/em\u003e\r\n\r\nEarly-Stage Germ-Cell Tumors – Management Approaches – \u003cem\u003eDaniel D. Joyce, MD, MS\u003c\/em\u003e\r\n\r\nMetastatic Germ-Cell Cancer – Management Approaches – \u003cem\u003eNirmish Singla, MD, MSCS, FACS\u003c\/em\u003e\r\n\r\nPenile Cancer Part 1 – Organ Confined Disease – \u003cem\u003eReza Nabavizadeh, MD\u003c\/em\u003e\r\n\r\nPenile Cancer Part 2 – Adavanced Disease – \u003cem\u003eReza Nabavizadeh, MD\u003c\/em\u003e\r\n\r\nEnhanced Recovery After Surgery – \u003cem\u003eSaum B. Ghodoussipour, MD\u003c\/em\u003e\r\n\r\nPalliative and End-of-Life Care – Integrating Early with Curative-Intent Pathways – \u003cem\u003eKristen R. Scarpato, MD, MPH\u003c\/em\u003e\r\n\r\nArtificial Intelligence Applications for GU Cancers – \u003cem\u003eAbhinav Khanna, MD\u003c\/em\u003e\r\n\r\nOptimizing Sexual Health in Women Undergoing Radical Cystectomy – \u003cem\u003eAriana L. Smith, MD\u003c\/em\u003e\r\n\r\nPediatric Urologic Oncology – \u003cem\u003eLeslie M. Peard, MD\u003c\/em\u003e\r\n\r\nFrailty Assessments in GU Cancer Patients – \u003cem\u003eLogan Briggs, MD\u003c\/em\u003e\r\n\r\nDiagnosis and Management of Benign Adrenal Lesions – \u003cem\u003eMarshall Strother, MD\u003c\/em\u003e\r\n\r\nMalignant Adrenal Masses for the Urologist – \u003cem\u003eJacob Tallman, MD\u003c\/em\u003e\r\n\r\nSmoking Cessation in Genitourinary Cancer Care – \u003cem\u003eMarc Bjurlin, DO, MSc\u003c\/em\u003e\r\n\r\nOptimizing Performance and Efficiency in Robotic-Assisted Procedures – \u003cem\u003eJanet Kukreja, MD, MPH, FACS\u003c\/em\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163711897698,"sku":"MED-AMB09702","price":35.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Oakstone-Update-in-Urologic-Oncology-2026.jpg?v=1785419541","url":"https:\/\/meducourse.com\/products\/oakstone-update-in-urologic-oncology-2026","provider":"Meducourse","version":"1.0","type":"link"}